Seres Therapeutics Inc
NASDAQ:MCRB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Seres Therapeutics Inc
Interest Expense
Seres Therapeutics Inc
Interest Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Seres Therapeutics Inc
NASDAQ:MCRB
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Expense
$2.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Expense
$1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Expense
$2.8B
|
CAGR 3-Years
25%
|
CAGR 5-Years
17%
|
CAGR 10-Years
10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Expense
$13.3m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-17%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Expense
$43.8m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
12%
|
|
Seres Therapeutics Inc
Glance View
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 333 full-time employees. The company went IPO on 2015-06-26. The firm is engaged in developing a class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The firm's lead product candidate, SER-109, is designed to reduce further recurrences of Clostridioides difficle infection (CDI). The company is also developing therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, a microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to reduce incidences of gastrointestinal infections, bloodstream infections and graft versus host disease (GvHD) in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). In addition, using its microbiome therapeutics platform, the Company is developing SER-287 and SER-301 to treat ulcerative colitis (UC).
